Thai State Council Takes Up Compulsory Licensing Issue
This article was originally published in PharmAsia News
Executive Summary
Thailand's Council of State has taken up the issue of the whether the Public Health Ministry's policy of imposing compulsory licensing on foreign drug makers is legal. Sanofi Aventis of France, seeking to protect the patent on its Taxotere (doxetaxel) breast cancer drug, earlier petitioned the government to review the ministry's CL policy, which the company said violates two articles of the nation's Patent Act. The Commerce Ministry, given authority over such issues by the act, sought a ruling by the Council of State. The AIDS Access Foundation has urged the council to keep the CL policy in place. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.